Introduction

Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance with onset or first recognition during pregnancy (1). GDM is currently the most frequently diagnosed metabolic disorder in pregnant women (2), and its incidence is growing (3).

GDM is associated with several adverse pregnancy outcomes with macrosomia, shoulder dystocia, and neonatal hypoglycemia being the most common serious complications. Currently, there is no consensus on the screening criteria for GDM, and no specific universally accepted protocol exists with respect to the selective or global screening of pregnant women. Consequently, it is difficult to compare the prevalence of GDM among various populations. In particular, ethnicity has been proven to be an independent risk factor for GDM (4, 5). The goals of this study were to verify the usefulness of the World Health Organization (WHO) criteria for the diagnosis of GDM in a fragment of local population and the effectiveness of these criteria in preventing maternal and neonatal adverse outcomes in women younger than 35 years old without obvious risk factors for GDM.

Material and Methods

This was a retrospective population-based study involving 1360 pregnant women who delivered and who were observed in a university hospital in Istanbul from September 2012 to October 2013. Ethics Committee approval and informed consent has been taken. All the subjects were younger than 35 years and had no known risk factors for GDM. Women having chronic systemic illnesses, preexisting diabetes (type 1 or type 2), or multifetal gestations were excluded. All the women underwent oral glucose tolerance test (OGTT) screening between 24 and 28 weeks of pregnancy, and ultrasound examination was made to determine gestational age. In all cases, GDM was diagnosed according to the WHO criteria (4, 5). After a minimum of 8 h of overnight fasting, blood for glucose level determination was collected, after which the patient received 75 g glucose orally. An additional blood sample was collected for glucose level determination 2 h later. The WHO criteria define GDM as a fasting blood glucose >126 mg/dL, with a 2 h post dosing value >140 mg/dL. In case of GDM diagnosis, the patients underwent individualized diet and/or insulin
Table 1. Anthropometric, clinical, and biochemical features of all pregnant women in the study

<table>
<thead>
<tr>
<th></th>
<th>GDM (n=380)</th>
<th>No GDM (n=980)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>29.3±3.4</td>
<td>30.8±3.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.9±1.9</td>
<td>21.4±1.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Gravida, n</td>
<td>2.5±0.7</td>
<td>2.5±0.6</td>
<td>0.934</td>
</tr>
<tr>
<td>Week at OGTT</td>
<td>27.1±1.2</td>
<td>27.1±0.8</td>
<td>0.230</td>
</tr>
<tr>
<td>Fasting glucose (mg/dL)</td>
<td>91.4±8.97</td>
<td>79.4±5.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>2-h postprandial glucose (mg/dL)</td>
<td>140.5±21.8</td>
<td>111.6±18.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Weight gain at OGTT (kg)</td>
<td>9.8±3.4</td>
<td>7.0±2.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Weight gain at delivery (kg)</td>
<td>14.3±3.3</td>
<td>12.0±2.7</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Values are mean±SD. GDM: gestational diabetes mellitus; BMI: body mass index; OGTT: oral glucose tolerance test.

Results

The present study included 1360 pregnant women who underwent screening for GDM. Out of the 1360 women screened between September 2012 and October 2013, 380 (28%) women were diagnosed with GDM, whereas the remaining 980 (72%) had no GDM. Anthropometric, clinical, and biochemical features of all pregnant women having no GDM risk factors are shown in Table 1.

Maternal age, body mass index (BMI), and weight gain at the time of 75-g OGTT and at delivery were remarkably different between the groups. Glycemic levels in both fasting samples and following the glucose load were also remarkably higher in the GDM group. Out of the 380 women with GDM, 102 (27%) received insulin, whereas the remaining 278 (73%) were treated with self-observing of blood glucose levels (fasting and 1 h after each meal) daily with a glucometer. Subsequent follow-ups were conducted for all patients biweekly or more frequently as indicated. Treatment outcomes were evaluated according to the American Diabetes Association recommendations (6).

All demographic characteristics (age, parity, family history of diabetes, and self-reported prepregnancy weight) of the patients were obtained from their existing records. Birth mode (cesarean or vaginal delivery) and labor induction, preterm delivery (delivery before 37 weeks of gestation), gestational hypertension, preeclampsia, polyhydramnios, and oligohydramnios were also documented from these records. The recorded adverse fetal outcomes were infant death, stillbirth, dystocia, bone fracture, nerve palsy, admission to the neonatal intensive care unit (NICU), respiratory complications [including respiratory distress syndrome (RDS) and transient tachypnea of newborn (TTN)] that increased birth weight, macrosomy (birth weight >4000 g), large for gestational age (LGA, defined as birth weight > the 90th percentile on standard charts), small for gestational age (SGA, defined as birth weight < the 10th percentile on standard charts), and metabolic complications including hypocalcemia, hemoglobin level ≥20 g/dL, hypoglycemia (blood glucose level ≤35 mg/dL), and hyperbilirubinemia requiring phototherapy.

Logistic regression analysis was performed to test whether the diagnosis of GDM in women younger than 35 years without risk factors influenced maternal and neonatal adverse events despite achieving adequate glycemic control. GDM was the dependent variable in this analysis. Maternal outcomes in women included in the study are shown in Table 2a.

In the GDM group, the rate of primary cesarean section (CS) was significantly higher than that in the non-GDM group (29.6% vs 15.3%; odds ratio (OR)=2.35, 95% confidence interval (CI) 1.53-3.64, p<0.001); furthermore, the difference remained significant after correcting for age, prepregnancy BMI, and parity (Table 2a). The rate of CS after vaginal labor induction was alike in both groups. Secondary CS in women who had previously delivered via CS was strongly associated with GDM [adjusted odds ratio (AOR)=5.05, 95% CI 2.11-12.08, p<0.001]. In unadjusted analyses, the combination of gestational hypertension and preeclampsia was associated with GDM (OR=2.44, 95% CI 1.03-5.65, p=0.037), as was preterm delivery (OR=2.43, 95% CI 1.11-5.29, p=0.025); however, these associations were insignificant subsequent to adjusting for age, prepregnancy BMI, and parity (for the combination of gestational hypertension and preeclampsia AOR=2.03, 95% CI 0.83-4.97, p=0.120, for preterm delivery AOR=1.65, 95% CI 0.32-8.51, p=0.549). The diagnosis of GDM was associated with polyhydramnios even after correcting for age, prepregnancy BMI, and parity (AOR=4.48, 95% CI 1.20-16.73, p=0.025). No association was observed between fetal distress and oligohydramnios (Table 2a). Fetal/neonatal outcomes in the women included in the study are shown in Table 2b.

No stillbirth, neonatal deaths, or nerve palsy occurred among the infants in either group. The newborns of women with GDM showed a significantly higher weight (p<0.001) after correcting for maternal age, prepregnancy BMI, and gestational age at birth. Additionally, the diagnosis of GDM was strongly associated with admission to NICU following adjustment for age, BMI, parity, and neonatal weight (AOR=4.39, 95% CI 1.44-13.37, p=0.009). Nevertheless, no significant association was observed between the groups regarding other important perinatal outcomes such as shoulder dystocia and bone fracture (AOR=1.47, 95% CI 0.81-
There was no remarkable difference between the groups regarding SGA or macrosomia, yet significantly more infants in the GDM group were LGA (AOR=3.53, 95% CI 1.34-9.34, p=0.011). Neonatal respiratory problems at delivery, including RDS and TTN, were not significantly different between the two groups. GDM appeared to be associated with
metabolic complications (OR=2.86, 95% CI 1.05-7.80, p=0.040), although this association was not observed after correcting for age, BMI, parity, and gestational age at birth. All significant associations were independent of BMI; however, prepregnancy BMI was correlated with primary CS (r=0.103, p=0.017), neonatal weight (r=0.122, p=0.005), and LGA (r=0.113, p=0.009) independently from GDM via Pearson’s test.

Discussion

GDM is a type of diabetes and is the most common metabolic disorder seen during gestation occurring in 1%-14% of pregnancies (1). The prevalence of GDM continues to increase globally (7). GDM may cause serious morbidities both for mother and infant (8). Women with GDM have been reported to have increased rates of stillbirth, polyhydramnios, gestational hypertension, macrosomia, and cesarean delivery (9). GDM usually resolves after delivery, but it appears that the risk of recurring GDM and type 2 diabetes mellitus is increased in subsequent pregnancies, along with cardiovascular risk later in life (10, 11). Although the precise role of the risk factors related to GDM (multiparity, obesity) has not yet been entirely defined, they may be included in the classification of pregnancy-related or maternal factors (12). Early diagnosis of metabolic disorder is highly critical for the prevention of fetal and maternal complications (5, 13).

Since the adoption of the 2 h 75-g OGTT in pregnancy, the WHO recommended the same diagnostic limit values accepted for the identification of impaired glucose tolerance in non-pregnant women (14, 15). The WHO stated in 1999 that GDM encompasses both impaired glucose tolerance and diabetes (fasting plasma glucose ≥7 mmol/dL or ≥126 mg/dL; 2 h plasma glucose ≥7.8 mmol/dL or 140 mg/dL, respectively) (16) and has maintained their recommendations to date. With early diagnosis and good medical and obstetric care, the risks of higher perinatal mortality and infant morbidity rates associated with GDM should be minimized (17, 18). In patients with persistent maternal hyperglycemia, the use of additional oral medications, insulin treatment, and lifestyle changes has shown improved perinatal outcomes. Medical nutrition counseling and diet therapy to achieve an overall healthy lifestyle are valuable in the management of GDM (19-21) and can optimize maternal and fetal outcomes (22, 23).

In this study, our aims were to verify the effectiveness of the WHO GDM diagnostic criteria in preventing adverse maternal and neonatal outcomes in women younger than 35 years with the WHO GDM diagnostic criteria in preventing adverse maternal and neonatal outcomes (22, 23).

While women with GDM were significantly older and had a significantly higher BMI compared with their non-GDM counterparts, all observed associations remained significant after correcting for age and prepregnancy BMI, indicating that GDM was an independent risk factor. Our findings confirm and extend previous observations that GDM and increased BMI are independently associated with adverse maternal and neonatal outcomes, with their combination having a greater impact. Some adverse pregnancy outcomes in our study were correlated with prepregnancy BMI even within the normal range (<25 kg/m²) and independently from GDM. Our results show that most cases of GDM were diagnosed at baseline and at 2 h of the OGTT timeframe.

The interpretation of the results of this study is limited by the small sample size. Higher rates of preterm delivery observed among the GDM cases together with the increase in both CS and NICU admission rates may be considered to be the result of excessive medical interventions. However, the higher rate of polyhydramnios and LGA in women with GDM accounted for the higher number of CS in this group, whereas overtreatment would not help explain the neonatal primary outcomes, such as LGA, and higher neonatal weight. All outcomes in our GDM group are remarkably lower with respect to those observed in other studies of GDM in the general population (25).

There are only a few studies on GDM prevalence reported from Turkey. In the study by Akbay et al. (26), a prevalence of 8.9% was reported, whereas Köşüş et al. (27) reported a prevalence of 8.6%. In both these studies, GDM was diagnosed after a 50-g glucose screening test followed by a 100-g glucose OGTT in two steps. While only a few studies using the 75-g OGTT according to the WHO criteria have been reported in literature, this method has the advantage of being both a screening and diagnostic test and being performed in a single step. Additional, larger studies are needed to confirm our findings.

Ethics Committee Approval: Ethics committee approval was received for this study from the ethics committee of Istanbul Medipol University.

Informed Consent: Written informed consent was obtained from patients who participated in this study.

Peer-review: Externally peer-reviewed.


Conflict of Interest: No conflict of interest was declared by the authors.

References


